How should a fundic gland polyp identified on upper endoscopy be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Fundic Gland Polyps

Fundic gland polyps (FGPs) do not require routine excision or surveillance unless they have atypical features—specifically, size >1 cm, antral location, ulceration, dysplastic appearance, or unusual endoscopic characteristics warrant resection. 1

Initial Endoscopic Assessment

When FGPs are identified, document the following systematically:

  • Number of polyps (particularly note if >20 polyps present)
  • Location (typical: fundus/corpus; atypical: antrum)
  • Size of largest polyp (threshold: 1 cm)
  • Morphology and appearance (pale, smooth, glassy, translucent with lacy blood vessels and fine grey dots)
  • Representative photographs 1

The diagnosis is typically made endoscopically based on characteristic appearance: pale, smooth, glassy polyps that are translucent or lighter than surrounding mucosa, with visible lacy blood vessels through the surface and a pattern of fine grey dots 1.

When to Biopsy or Resect

Biopsy confirmation should be obtained when there is diagnostic uncertainty 1. However, most typical-appearing FGPs do not require tissue sampling.

Mandatory excision is indicated for:

  • Polyps >1 cm in size (dysplasia risk: 1.9%; focal cancer risk: 1.9%) 1
  • Antral location (atypical for FGPs)
  • Ulceration present
  • Dysplastic appearance (irregular surface/vascular architecture)
  • Unusual appearance that questions the diagnosis 1

If multiple polyps are present, resect the largest polyps and sample representative smaller ones 2, 1.

Screening for Familial Adenomatous Polyposis (FAP)

Evaluate for FAP if any of the following are present:

  • >20 polyps (large numbers)
  • Age <40 years at presentation
  • Dysplastic-appearing polyps
  • Presence of duodenal adenomas 1

This is critical because FAP-associated FGPs carry malignancy risk, unlike sporadic FGPs 1.

PPI Management

Patients on long-term PPIs should be re-evaluated for:

  • Appropriateness of PPI indication
  • Appropriate PPI dose
  • Alternative treatment options 1

However, patients using PPIs for valid indications do not need to discontinue these medications solely due to FGPs 3. FGPs are associated with long-term PPI use and can spontaneously regress when PPIs are stopped 1.

Surveillance Recommendations

There is no role for surveillance gastroscopy for typical sporadic FGPs 1. The exception is FAP patients, who require ongoing surveillance 1.

For patients with resected dysplastic FGPs:

  • Low-grade dysplasia with complete resection: Follow-up at 1 year 3
  • High-grade dysplasia with complete resection: Follow-up at 6 months 3
  • Incomplete resection or biopsy only: Follow-up at 6 months for low-grade dysplasia, 3 months for high-grade dysplasia 3

Assessment of Background Mucosa

When FGPs are present, evaluate the surrounding gastric mucosa systematically 3. FGPs have no association with H. pylori infection or gastritis 1, which helps distinguish them from hyperplastic polyps.

If adenomas or hyperplastic polyps coexist (different polyp types may occur together 3), obtain biopsies of surrounding mucosa to assess for gastric atrophy, intestinal metaplasia, and H. pylori 1.

Common Pitfalls to Avoid

  • Do not routinely biopsy or resect small (<1 cm), typical-appearing FGPs in the fundus/corpus—this is unnecessary and increases procedural time and cost
  • Do not schedule surveillance endoscopy for sporadic FGPs—this represents overutilization of resources
  • Do not miss FAP screening criteria—young patients with numerous polyps require genetic evaluation
  • Do not assume all fundic polyps are FGPs—antral location or atypical appearance should prompt tissue diagnosis to exclude adenomas or other pathology

References

2
Guideline

aga clinical practice update on high-quality upper endoscopy: expert review.

Clinical Gastroenterology and Hepatology, 2024

3
Research

AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026

Related Questions

How should gastric adenopathy be evaluated and managed?
What is the appropriate evaluation and management plan for biopsies taken from the antrum, fundus, and body of the stomach?
How should I manage an antral polyp in the setting of Helicobacter pylori infection?
What are the guidelines for managing a single prepyloric polyp identified on esophagogastroduodenoscopy (EGD)?
Which ICD‑10 codes should I use for a patient with a personal history of gastrointestinal polyps who is undergoing an esophagogastroduodenoscopy, and how should I code any polyps found during the exam?
Is Keltican (vitamin B‑complex containing thiamine and pyridoxine) safe to administer concurrently with standard tuberculosis therapy (isoniazid, rifampin, pyrazinamide, and ethambutol)?
What is the recommended valacyclovir dose for post‑exposure prophylaxis of varicella in healthy and immunocompromised patients?
How can deterioration be recognized in the intensive care unit, including assessment of airway, breathing, circulation, and Glasgow Coma Scale?
Can finerenone cause hyperkalemia?
In a 55-year-old woman with hypertension resistant to an ACE inhibitor, beta‑blocker, and calcium‑channel blocker, who has borderline hypokalemia, normal sodium, elevated creatinine, left‑ventricular hypertrophy on ECG, no abdominal bruit, and normal fundoscopic findings, what is the most likely cause of her secondary hypertension?
What oral antibiotic medications can be used in a neonate when intravenous (IV) access is not feasible?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.